TICKERNERD
Menu
LLYLLYHealthcare · Drug Manufacturers - General

LLY Stock Forecast: Eli Lilly & Co. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1,116
−0.65% on the day

The 30 Wall Street analysts covering Eli Lilly & Co. hold a median 12-month price target of $1,376 — +23.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$994.9B
Ticker Nerd rank
90 / 100
Median analyst target
$1,376
Analysts covering
30
Revenue$23.0B+47.7% y/y
Operating income$12.5B
Net income$7.1B
Free cash flow$4.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−8.0%
YTD
+4.3%
1Y
+48.5%
From 52W high
−12.9%
From 52W low
+57.1%
$710
$1,280
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LLY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eli Lilly & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Volatility
98
Value
97
Revisions
90
Growth
88
Momentum
80
Issuance
40
Accruals
21
Size
0

Quality (98): The business earns solid, repeatable profits on what it owns.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LLY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LLY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$800$1,000$1,200$1,400$1,600Oct 25Jan 26Apr 26Jul 26LLYHigh $1,600Median $1,376Low $930

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says30 analysts
24 Buy4 Hold2 Sell
Low $930Median $1,376High $1,600

The green dot is the last close — the median target sits +23.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsReduce$850 → $940
7 Aug 2026Truist SecuritiesMaintainsBuy$1,370 → $1,376
7 Aug 2026Truist SecuritiesMaintainsBuy—
6 Aug 2026Cantor FitzgeraldMaintainsOverweight—
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$1,350 → $1,410
6 Aug 2026Wells FargoMaintainsOverweight—
6 Aug 2026Wells FargoMaintainsOverweight$1,280 → $1,330
15 July 2026CitigroupMaintainsBuy$1,500 → $1,600
15 July 2026CitigroupMaintainsBuy—
14 July 2026BernsteinMaintainsOutperform$1,300 → $1,385
14 July 2026BernsteinMaintainsOutperform—
13 July 2026GuggenheimMaintainsBuy—
13 July 2026GuggenheimMaintainsBuy$1,235 → $1,273
13 July 2026UBSMaintainsBuy$1,250 → $1,425
13 July 2026UBSMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsBuy$1,251 → $1,334
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$1,344 → $1,347
8 July 2026RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LLY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LLY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Eli Lilly & Co. returned +48.5% against +17.5% for the S&P 500, dividends included.

LLY vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26LLYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LLY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.4%
Analysts raising
13
Analysts cutting
10
Fundamentals

Eli Lilly & Co. (LLY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
37.5×

Cheaper than 20% of US stocks

Price / sales
12.5×

Cheaper than 12% of US stocks

Price / book
29.4×

Cheaper than 3% of US stocks

EV / EBITDA
24.9×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
47.7%

Higher than 85% of US stocks

Earnings growth (YoY)
25.3%

Higher than 62% of US stocks

Gross margin
85.8%

Higher than 94% of US stocks

Operating margin
54.2%

Higher than 97% of US stocks

Net margin
33.5%

Higher than 92% of US stocks

Returns & dividend
Return on equity
102.3%

Higher than 96% of US stocks

Return on assets
20.4%

Higher than 99% of US stocks

Dividend yield
0.6%

Higher than 12% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eli Lilly & Co. (LLY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eli Lilly & Co. has a market value of $994.9B and an enterprise value of $1.0T.

  • Revenue in the twelve months to 30 June 2026: $79.7B. The latest quarter grew 47.7% year on year.

  • Net income over the same four quarters: $26.7B, a 33.5% net margin.

  • Diluted earnings per share, trailing twelve months: $29.80.

  • Free cash flow in the twelve months to 30 June 2026: $13.6B.

  • Eli Lilly & Co. spent $6.2B on share buybacks and $5.8B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 891.5M.

  • Trailing P/E: 37.5×; forward P/E: 23.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.62%, paying out 22% of earnings.

  • Eli Lilly & Co. employs 50,000 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

LLY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
LLYEli Lilly & Co.$994.9B
90
JNJJohnson & Johnson$640.0B
91
ABBVAbbVie, Inc.$454.3B
96
MRKMerck & Co., Inc.$357.2B
82
AMGNAmgen, Inc.$203.4B
90
GILDGilead Sciences, Inc.$178.4B
93
PFEPfizer Inc.$157.6B
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eli Lilly & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LLY news & analysis

People are taking bootleg versions of an Eli Lilly drug that isn't approved yet. Ohio wants it to stop.

WSJ · 14 Sept 2026negative

Bootleg versions of an experimental, not-yet-approved Eli Lilly drug are flooding the market, and Ohio regulators are seeking to curb the supply of these unauthorized copies.

Why it matters — A watcher of Eli Lilly would care because unauthorised counterfeits of an unapproved experimental drug raise concerns about product integrity and could complicate the drug's market rollout.

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

The Motley Fool · 14 Sept 2026neutral

Novartis announced unfavorable news regarding its Lp(a)-lowering drug, pelacarsen. Eli Lilly is also developing its own therapy aimed at lowering Lp(a).

Why it matters — Because Eli Lilly is developing a competing Lp(a)-lowering therapy, the outcome of Novartis's drug could influence the competitive landscape for Lilly's pipeline program.

Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst

The Motley Fool · 13 Sept 2026negative

Novo Nordisk launched its Wegovy pill in early 2026, and it has been very well received. Eli Lilly followed with a competing pill, Foundayo, which has been slower to gain traction.

Why it matters — A LLY watcher would care because a rival's weight-loss pill is gaining traction while Eli Lilly's comparable product is lagging in adoption.

Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Zacks Investment Research · 11 Sept 2026positive

Eli Lilly's immunology portfolio is showing steady revenue growth, with pipeline expansion and acquisitions broadening its next wave of growth engines beyond its GLP-1 franchise.

Why it matters — A LLY watcher would care because the company is building additional revenue drivers in immunology to complement and diversify beyond its well-known GLP-1 products.

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

PRNewsWire · 11 Sept 2026positive

Eli Lilly and Company announced the successful completion of its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant depression.

Why it matters — The acquisition expands Lilly's pipeline into treatment-resistant depression and other mental health conditions through AtaiBeckley's investigational neuroplastogen programs.

FAQ

Frequently asked questions about LLY stock

What is the LLY stock price forecast for 2026-2027?

The 30 Wall Street analysts covering Eli Lilly & Co. have a median 12-month price target of $1,376, with estimates ranging from $930 to $1,600. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LLY stock a buy right now?

Of the 30 analysts covering Eli Lilly & Co., 24 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Eli Lilly & Co. 90 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LLY?

As at 12 Sept 2026, Eli Lilly & Co. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will LLY stock go up?

No one can know that. What the data says: the median 12-month target from 30 analysts implies +23.3% from the last close, and Ticker Nerd's factor model ranks Eli Lilly & Co. 90 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LLY stock forecast for 2030?

No analyst covering Eli Lilly & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LLY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $930 to $1,600 over the next 12 months.

How has LLY stock performed over the past year?

Eli Lilly & Co. returned +48.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eli Lilly & Co. do?

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide.

What is the latest news on LLY?

The most recent item we track (WSJ, 14 Sept 2026): "People are taking bootleg versions of an Eli Lilly drug that isn't approved yet. Ohio wants it to stop.". Bootleg versions of an experimental, not-yet-approved Eli Lilly drug are flooding the market, and Ohio regulators are seeking to curb the supply of these unauthorized copies.

Company

About Eli Lilly & Co.

Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.

CEO Mr. David A. Ricks · 50,000 employees · United States · https://www.lilly.com